Rheumatoid Arthritis Treatment: Targeting Remission everydayhealth.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from everydayhealth.com Daily Mail and Mail on Sunday newspapers.
AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ for the treatment …
– ABBVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ (upadacitinib) for the
To Improve PsA Outcomes, Address Common Comorbidities medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
RA disease activity assessment
Keeping your rheumatoid arthritis well-controlled is one of the best things you can do for your joints and your heart. According to a study published in the journal
Arthritis & Rheumatology, people whose RA was in remission were 53 percent less likely to experience a serious cardiovascular event during the study’s three-year follow-up period.
Your rheumatologist should be assessing your RA disease activity at least once a year using a scoring tool that is approved by the American College of Rheumatology. There are many different ways to measure RA disease activity, but each involves different combinations of assessing factors like counts of painful and swollen joints, blood tests for inflammatory markers, and patients’ and physicians’ reports of pain and function in everyday life. They include: